$563.95
0.45% yesterday
Nasdaq, May 13, 10:05 pm CET
ISIN
US46120E6023
Symbol
ISRG
Sector

Intuitive Surgical Target price 2025 - Analyst rating & recommendation

Intuitive Surgical Classifications & Recommendation:

Buy
59%
Hold
38%
Sell
3%

Intuitive Surgical Price Target

Target Price $575.83
Price $563.95
Potential 2.11%
Number of Estimates 25
25 Analysts have issued a price target Intuitive Surgical 2026 . The average Intuitive Surgical target price is $575.83. This is 2.11% higher than the current stock price. The highest price target is $675.00 19.69% , the lowest is $470.00 16.66% .
A rating was issued by 34 analysts: 20 Analysts recommend Intuitive Surgical to buy, 13 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Intuitive Surgical stock has an average upside potential 2026 of 2.11% . Most analysts recommend the Intuitive Surgical stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029


Dec '24 2025
Estimates
Revenue Billion $ 8.35 9.66
17.24% 15.63%
EBITDA Margin 33.58% 40.72%
8.64% 21.26%
Net Margin 27.55% 25.47%
8.87% 7.55%

26 Analysts have issued a sales forecast Intuitive Surgical 2025 . The average Intuitive Surgical sales estimate is $9.7b . This is 10.82% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $9.8b 12.81% , the lowest is $9.5b 8.99% .

This results in the following potential growth metrics:

Revenue Estimates

2024 $8.4b 17.24%
2025 $9.7b 15.63%
2026 $11.1b 15.40%
2027 $12.9b 15.42%
2028 $14.6b 13.52%
2029 $16.0b 9.26%

21 Analysts have issued an Intuitive Surgical EBITDA forecast 2025. The average Intuitive Surgical EBITDA estimate is $3.9b . This is 33.25% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $4.8b 63.39% , the lowest is $3.3b 12.56% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $2.8b 27.37%
2025 $3.9b 40.22%
2026 $4.5b 15.44%
2027 $5.4b 19.36%
2028 $6.4b 17.52%
2029 $7.2b 12.62%

EBITDA Margin

2024 33.58% 8.64%
2025 40.72% 21.26%
2026 40.73% 0.02%
2027 42.12% 3.41%
2028 43.61% 3.54%
2029 44.95% 3.07%

11 Intuitive Surgical Analysts have issued a net profit forecast 2025. The average Intuitive Surgical net profit estimate is $2.5b . This is 0.63% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.7b 9.53% , the lowest is $2.3b 6.30% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $2.3b 27.63%
2025 $2.5b 6.90%
2026 $2.9b 19.74%
2027 $3.5b 19.09%
2028 $4.1b 16.62%

Net Margin

2024 27.55% 8.87%
2025 25.47% 7.55%
2026 26.43% 3.77%
2027 27.27% 3.18%
2028 28.01% 2.71%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029


Dec '24 2025
Estimates
Earnings Per Share $ 6.42 6.86
27.63% 6.85%
P/E 82.17
EV/Sales 20.47

11 Analysts have issued a Intuitive Surgical forecast for earnings per share. The average Intuitive Surgical EPS is $6.86 . This is 0.59% higher than earnings per share in the financial year 2024. The highest EPS forecast is $7.47 9.53% , the lowest is $6.39 6.30% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $6.42 27.63%
2025 $6.86 6.85%
2026 $8.22 19.83%
2027 $9.79 19.10%
2028 $11.41 16.55%

P/E ratio

Current 82.72 18.56%
2025 82.17 0.66%
2026 68.63 16.48%
2027 57.62 16.04%
2028 49.41 14.25%

Based on analysts' sales estimates for 2025, the Intuitive Surgical stock is valued at an EV/Sales of 20.47 and an P/S ratio of 20.93 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 22.69 25.36%
2025 20.47 9.77%
2026 17.74 13.35%
2027 15.37 13.36%
2028 13.54 11.91%
2029 12.39 8.47%

P/S ratio

Current 23.19 23.75%
2025 20.93 9.76%
2026 18.14 13.35%
2027 15.71 13.36%
2028 13.84 11.91%
2029 12.67 8.47%

Current Intuitive Surgical Upgrades & Downgrades

Analyst Rating Action Date
Barclays
Overweight
Overweight
Unchanged Apr 24 2025
RBC Capital
Outperform
Outperform
Unchanged Apr 23 2025
Baird
Outperform
Outperform
Unchanged Apr 23 2025
Piper Sandler
Overweight
Overweight
Unchanged Apr 23 2025
Evercore ISI Group
In-Line
In-Line
Unchanged Apr 23 2025
Truist Securities
Buy
Buy
Unchanged Apr 23 2025
Baird
Outperform
Outperform
Unchanged Mar 18 2025
Analyst Rating Date
Unchanged
Barclays:
Overweight
Overweight
Apr 24 2025
Unchanged
RBC Capital:
Outperform
Outperform
Apr 23 2025
Unchanged
Baird:
Outperform
Outperform
Apr 23 2025
Unchanged
Piper Sandler:
Overweight
Overweight
Apr 23 2025
Unchanged
Evercore ISI Group:
In-Line
In-Line
Apr 23 2025
Unchanged
Truist Securities:
Buy
Buy
Apr 23 2025
Unchanged
Baird:
Outperform
Outperform
Mar 18 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today